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Abstract
Background: Survivin, one of the strongest apoptosis inhibitors, plays a critical role in the development and
progression of hepatocellular carcinoma (HCC). By comparison, relatively little is known about the effect of survivin
gene polymorphisms on HCC susceptibility. Our study aimed to investigate the association of survivin gene
polymorphisms with the risk of HCC in Chinese han population.
Methods: A case-control study was conducted in Chinese han population consisting of 178 HCC cases and 196
cancer-free controls. Information on demographic data and related risk factors was collected for all subjects.
Polymorphisms of the survivin gene, including three loci of rs8073069, rs9904341 and rs1042489, were selected and
genotyped by a polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP) technique.
Association analysis of genotypes/alleles and haplotypes from these loci with the risk of HCC was conducted under
different genetic models.
Results: Using univariate analysis of rs8073069, rs9904341 and rs1042489 under different genetic models, no
statistically significant difference was found in genotype or allele distribution of HCC cases relative to the controls
(P > 0.05). Linkage disequilibrium (LD) analysis showed that these loci were in LD. Multivariate logistic regression
indicated that with no G-C-T haplotype as reference, the haplotype of G-C-T from these loci was associated with a
lower risk for HCC under the recessive model (OR = 0.46, 95% confidence interval (CI): 0.24~0.90, P = 0.023). Both
HBsAg+ and the medical history of viral hepatitis type B were risk factors for HCC. However, no statistically
significant haplotype-environment interaction existed.
Conclusions: No association between rs8073069, rs9904341 or rs1042489 in survivin gene and the risk of HCC is
found in Chinese han population, but rs8073069G-rs9904341C- rs1042489T is perhaps a protective haplotype for
HCC.
Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer in the world and the third most common
cause of cancer-related death, which represents a major
and constantly rising health burden throughout the
world. In addition, HCC shows great geographical varia-
tion, with a very high incidence in China, where approxi-
mately 55% of annual new cases worldwide emerge [1,2].
Nowadays, the exact mechanism of hepatocarcinogenesis
is still incompletely understood. However, a number of
relevant molecules alter in some biological signals in the
preneoplastic hepatocytes, especially the overactivation of
anti-apoptotic signals, which disrupts the balance
between survival and apoptotic signals [3]. It’sw i d e l y
accepted that apoptosis plays a key role in cell or tissue
homeostasis [4,5], dysregulation of apoptosis may induce
the accumulation of virtually immortal cells and can ulti-
mately lead to many human disorders, including cancer
[6].
Survivin is a novel member of the inhibitor of apoptosis
family of proteins (IAPs), containing a single baculovirus
IAP repeat (BIR) domain [7]. It is involved in cell cycle
regulation, inhibition of the apoptosis pathways and
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any medium, provided the original work is properly cited.microtubule stability [8], playing a critical role in the
initiation and progression of tumorigeness. Survivin
blocks both death receptor and mitochondrial apoptosis
pathways, by directly inhibiting caspase-3 and caspase-7
as well as by interfering with caspase-9 activity/proces-
sing [9]. Furthermore, survivin inhibits apoptosis initiated
by various apoptotic stimuli such as IL-3, Fas, Bax, TNF-
a, anticancer drugs, and X-irradiation [10,11]. In addi-
tion, it’s reported that survivin was associated with angio-
genesis [12], which is critical in carcinogenesis. Survivin
is ubiquitous in embryonic or fetal tissues while unde-
tectable in most terminally differentiated normal adult
tissues [7]. By contrast, it is overexpressed in most
human cancers including HCC [13-17]. Moreover,
increased survivin expression in human malignancies is
considered to be an important marker for aggressive and
chemoresistant disease, thus signaling poor prognosis
[8,18-21].
Survivin is expressed in a cell cycle-regulated manner,
with a peak in the G2/M phase of the cell cycle, while it
rapidly declines in the G1 phase [22]. This is largely tran-
scriptionally controlled and involves cell cycle-dependent
elements (CDEs) and cell cycle homology regions (CHRs)
located in survivin gene promoter [23]. Several single
nucleotide polymorphisms (SNPs) have been identified in
survivin gene, such as -31G/C, -625G/C and -644C/T.
-31G/C polymorphism is a common mutation in cancer
cell lines leading to overexpression of survivin and the
aberrant cell cycle-dependent transcription, mediated via
functional disruption of binding at the CDE/CHR repres-
sor motifs [24]. Several population-based studies indi-
cated survivin gene polymorphisms were associated with
human cancers [25-27]. However, to date, there was only
one report on the relationship between survivin gene
polymorphisms and the risk of HCC [28]. No similar
study has been conducted yet in Chinese population.
Based on the key role of survivin in carcinogenesis and
the association of survivin gene polymorphisms with its
expression and other cancers, we hypothesized that poly-
morphisms in survivin gene might modulate susceptibil-
ity to HCC. To test this hypothesis, we investigated the
association between survivin gene polymorphisms and
the risk of HCC in Chinese han population.
Methods
Study Population and Samples Collection
This case-control study consisted of 178 HCC patients
and 196 cancer-free controls. All subjects were unrelated
han nationality living in Haimen city, Jiangsu province.
HCC patients were diagnosed by doctors according to
the standards established byC h i n e s eS o c i e t yo fL i v e r
Cancer (CSLC) [29]. Controls were matched with the
patients in terms of age and sex, excluding those with
medical history of surgery or chronic disease. Each
subject was personally face-to-face interviewed by trained
interviewers for information on demographic data as well
as related risk factors such as tobacco smoking, alcohol
drinking, medical history of viral hepatitis type B, et al. In
addition, approximately 5 ml venous blood was drawn
from each subject and preserved at -80°C. This research
protocol was approved by the Ethics Committee of
Fudan University, with the number IRB# 08-08-0142.
DNA Extraction and Genotyping
The genomic DNA was extracted from each blood sam-
ple using RelaxGenne Blod DNA system (TIANGEN,
Beijing). Each polymorphism of rs8073069, rs9904341
and rs1042489 was identified via the polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP) technique. The primers for PCR, the restric-
tion enzymes, and the fragments length after digestion
are shown in Table 1. Amplification was carried out on a
GeneAmp PCR System PTC-200 (MJ, American), PCR
mixture contained 50 ng of DNA, 9.5 μl ddH2O, 12.5 μl
2 × Taq PCR Master Mix (Laifeng, Shanghai), 1 μl
10 μmol/l each primer. The annealing temperature was
60.2°C, 64.4°C and 64.4°C for rs8073069, rs9904341 and
rs1042489 respectively. PCR products were digested by
the corresponding restriction enzymes (ChinaGen,
Shenzhen) and then separated by 2.0~3.0% agarose
gel electrophoresis with ethidium bromide (EB). The
genotypes are shown in Figure 1, 2 and 3. For double-
checking and quality control, 5% of the samples were
randomly selected to perform the repeated assays, and
the results were 100% concordant.
Statistical Analysis
Genotypes were tested for Hardy-Weinberg equilibrium
by an online soft http://ihg.gsf.de/cgi-bin/hw/hwa1.pl. Dif-
ferences in the distribution of genotypes or alleles under
different genetic models (including dominant, recessive,
additive and multiple models) within groups were esti-
mated by univariate statistical analyses (chi-square test) on
SPSS 16.0. Pair-wise linkage disequilibrium (LD) between
SNPs was calculated by Haploview 4.1. In addition, haplo-
types analysis was carried out by multivariate logistic
regression analysis on Hapstat 3.0. The odds ratios (ORs)
and 95% confidence intervals (CIs) were presented for
association analysis. For all hypothesis tests, a two-tailed
significance level of P < 0.05 was considered statistically
significant.
Results
General Characteristics of the Subjects
A total of 374 subjects were recruited in our study,
including 178 HCC cases and 196 controls. Their general
characteristics are summarized in Table 2. There was no
significant difference in age or gender between cases and
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subjects were local ethnic han population in Haimen,
which indicated that both groups were comparable in
demographic characteristics. With regard to the risk fac-
tors, Table 2 shows that the distributions of drinking,
HBsAg+ and the medical history of viral hepatitis type B
were significantly different within groups. Additionally,
compared with the control subjects, the cases had a
higher rate of smoke-quitting, but no difference was
found between the proportion of subjects who never
smoked and current smokers.
Survivin Gene Polymorphisms of the Subjects
The genotype and allele frequencies of rs8073069,
rs9904341, rs1042489 in both HCC cases and controls are
presented in Table 3, 4 and 5. The genotype distributions
of the three polymorphisms didn’t significantly deviate
from that expected for a Hardy-Weinberg equilibrium (for
cases, c
2 = 2.239, 2.820 and 2.675 respectively; for con-
trols, c
2 = 0.143, 0.078 and 1.451 respectively; all P values
were higher than 0.05), illustrating that our subjects pre-
sented the source population well. We compared the gen-
otype or allele frequencies of every polymorphism within
groups under the dominant, recessive, additive and multi-
ple genetic models respectively. As shown in Table 3, 4
and 5, no significant differences were detected in the
distributions of genotypes or alleles between case and con-
trol groups.
Linkage Disequilibrium (LD) and Haplotype Analysis
LD analysis showed that rs8073069 and rs9904341 were in
strong LD, with the r
2 = 0.288, D’ = 0.916, D’ 95%CI
(0.830~0.960); rs8073069 and rs1042489 were also in
strong LD, with the r
2 = 0.425, D’ = 0.945, D’ 95%CI
(0.880~0.980); rs9904341 and rs1042489 were in weak LD,
with the r
2 = 0.026, D’ = 0.189, D’ 95%CI (0.070~0.290).
These results stated clearly the three identified survivin
gene polymorphisms were in LD.
With the help of multivariate logistic regression, factors
like drinking, HBsAg+, the medical history of viral hepati-
tis type B and different haplotypes constructed by
rs8073069-rs9904341-rs1042489 were included into mod-
els. As shown in Table 6 the recessive genetic model was
the optimal one, according to the lowest vale of Akaike’s
Information Criteria (AIC). With no G-C-T haplotype as
reference, it was found that the haplotype of G-C-T from
these loci was associated with a lower risk for HCC under
the recessive model (OR = 0.46, 95%CI: 0.24~0.90, P =
0.023), whereas none of other significant haplotypes were
found in this model. It also indicated that HBsAg+ and
the medical history of viral hepatitis type B were risk fac-
tors for HCC, with the OR being 27.03 (P < 0.001) and
55.16 (P < 0.001) respectively. However, no statistically
Table 1 PCR-RFLP-based assay of survivin SNPs
SNP Position Sequence of primer Enzyme Interpretation(bp)
rs8073069 -625 5’- GTYCATTTGTCCTTCATGCGC-3’ 5’- GGCAGAGGGTGCAGTGAGC-3’ Bstu I CC:164 CG:164,145 GG:145
rs9904341 -31 5’-GAGGACTACAACTCC CGGCAC-3’ 5’- GTAGAGATGCGGTGGTCCTTG-3’ Msp I GG:212,16 CC:120,92,16 CG:212,120,92,16
rs1042489 3’UTR 5’-GCTTACCAGGTGAGAAGTGAGG-3’ 5’-GTATCTGCCAGACGCTTCCTATC-3’ Msp I TT:476 TC:476,297,179 CC:297,179
Figure 1 The genotypes of rs8073069 by PCR-RFLP.
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detected under different genetic models, as shown in
Table 7.
Discussion
Suvivin gene, located in 17q25, containing three exons
and four introns, can encode an apoptosis inhibitor con-
sisting of 142 amino acids. Nowadays, several SNPs have
been identified in this gene [24]. The present case-con-
trol study explored the association of survivin gene poly-
morphisms with the risk of HCC in Chinese han
population for the first time. Our results suggested that
none of rs8073069, rs9904341 or rs1042489 polymorph-
isms in survivin gene correlated with the susceptibility
to HCC. The polymorphism of rs1042489 is in the 3’
untranslated region of survivin gene, studies about this
polymorphism haven’t been reported yet. Our result
showed that rs1042489 C/T polymorphism didn’t corre-
late with the risk of HCC, indicating this polymorphism
probably had nothing to do with the stability of survivin
mRNA or its translational efficiency [30]. However,
additional studies are required to clarify it.
The locus of rs8073069 (-625 G/C) is located in the
promoter region of survivin gene. There were two stu-
dies on the relationship between this polymorphism and
cancers, whereas no similar studies have been conducted
on HCC. Yang et al. [25] launched a case-control study
in Chinese population identifying that rs8073069-C
Figure 2 The genotypes of rs9904341 by PCR-RFLP.
Figure 3 The genotypes of rs1042489 by PCR-RFLP.
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Factors Case Control PO R (95%CI)
Age(mean ± SD) 53.31 ± 8.41 52.48 ± 8.47 0.343 -
Sex n(%) Male 136(76.4) 153(78.1) - -
Female 42(23.6) 43(21.9) 0.703 -
Smoking n(%) Never 71(39.9) 124(63.3) - 1
Current 47(26.4) 67(34.2) 0.400 1.23(0.76~1.97)
Quitting 60(33.7) 5(2.6) < 0.001 -
Drinking n(%) No 101(56.7) 135(68.9) - 1
Yes 77(43.3) 61(31.1) 0.015 1.69(1.11~2.58)
HBsAg+ n(%) No 48(27.0) 184(93.9) - 1
Yes 130(73.0) 12(6.1) < 0.001 41.53(21.22~81.26)
H
a n(%) No 105(59.0) 195(99.5) - 1
Yes 73(41.0) 1(0.5) < 0.001 135.57(18.58~989.35)
a The medical history of viral hepatitis type B
Table 3 Frequency of rs8073069 genotypes/alleles under different genetic models
Genetic model Genotypes/Alleles Case n(%) Control n(%) c
2(P) OR(95%CI)
Dominant CC 16(9.0) 12(6.1) - 1
CG/GG 162(91.0) 184(93.9) 1.11(0.293) 0.66(0.30~1.44)
Recessive CC/CG 77(43.3) 89(45.4) - 1
GG 101(56.7) 107(54.6) 0.18(0.676) 1.09(0.73~1.64)
Additive CC 16(9.0) 12(6.1) - 1
CG 61(34.3) 77(39.3) - 0.59(0.26~1.35)
GG 101(56.7) 107(54.6) 1.74(0.420) 0.71(0.32~1.57)
Multiple C 93(26.1) 101(25.8) - 1
G 263(73.9) 291(74.2) 0.01(0.911) 0.98(0.71~1.36)
Table 4 Frequency of rs9904341 genotypes/alleles under different genetic models
Genetic Model Genotypes/Alleles Case n(%) Control n(%) c
2(P) OR(95%CI)
Dominant CC 35(19.7) 52(26.5) - 1
CG/GG 143(80.3) 144(73.5) 2.47(0.116) 1.48(0.91~2.40)
Recessive CC/CG 135(75.8) 148(75.5) - 1
GG 43(24.2) 48(24.5) 0.01(0.940) 0.98(0.61~1.58)
Additive CC 35(19.7) 52(26.5) - 1
CG 100(56.2) 96(49.0) - 1.55(0.93~2.58)
GG 43(24.2) 48(24.5) 2.82(0.244) 1.33(0.74~2.41)
Multiple C 170(47.8) 200(51.0) - 1
G 186(52.2) 192(49.0) 0.80(0.372) 1.14(0.86~1.52)
Table 5 Frequency of rs1042489 genotypes/alleles under different genetic models
Genetic Model Genotypes/Alleles Case n(%) Control n(%) c
2(P) OR(95%CI)
Dominant CC 31(17.4) 27(13.8) - 1
CT/TT 147(82.6) 169(86.2) 0.94(0.331) 0.76(0.43~1.33)
Recessive CC/CT 130(73.0) 129(65.8) - 1
TT 48(27.0) 67(34.2) 2.28(0.131) 0.71(0.46~1.11)
Additive CC 31(17.4) 27(13.8) - 1
CT 99(55.6) 102(52.0) - 0.85(0.47~1.52)
TT 48(27.0) 67(34.2) 2.60(0.273) 0.62(0.33~1.18)
Multiple C 161(45.2) 156(39.8) - 1
T 195(54.8) 236(60.2) 2.25(0.133) 0.80(0.60~1.07)
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cinoma (ESCC), with the OR of CC genotype being
2.404 in contrast to GG genotype. Yang also described
different survivin expression levels between subgroups
with different rs8073069 G/C variants in ESCC patients.
His study suggested that rs8073069 G/C polymorphism
was associated with the susceptibility to ESCC, perhaps
by influencing survivin expression. However, Jang et al.
[26] discovered that rs8073069 G/C polymorphism was
not linked to the risk of lung cancer in Korea popula-
tion. Our study indicated that rs8073069 G/C poly-
morphism didn’t correlate with the HCC in Chinese han
population, this was consistent with Jang’s results, but
inconsistent with Yang’s study. One suggestive explana-
tion was that genetic susceptibility may be different to
diverse cancers, other molecular and cellular mechan-
isms were probably involved in survivin overexpression
in HCC. Besides, the negative results were perhaps due
to the relatively small sample size, and therefore addi-
tional studies with lager samples are needed to validate
our finding.
The locus of rs9904341 (-31 C/G) is located in survivin
gene promoter. Several studies on the association of this
polymorphism with cancers have been carried out. How-
ever their results were inconsistent. Jang et al. [26] dis-
covered that individuals with at least one rs9904341-G
allele had a significantly decreased risk for lung cancer
compared to those with CC genotype. Promoter assay
revealed G allele had a lower promoter activity than
rs9904341-C allele. His results indicated this polymorph-
ism regulated survivin expression, and thus modulated
susceptibility to lung cancer. Maria et al. [31] found the
association of this polymorphism with the risk of the
sporadic colorectal cancer (CRC). Moreover, homozy-
gotes for rs9904341-CC genotype expressed 1.6-fold
higher mRNA levels of survivin compared to cases with
other genotypes. Nonetheless, no correlation was found
of rs9904341 C/G polymorphism with some cancers
including ESCC, cervical cancer and acute myeloid leuke-
mia [25,32,33]. In addition, Bayram et al. [28] demon-
strated that there was no statistical association of
rs9904341 C/G polymorphism with the risk of HCC in
Turkish population. These inconsistent results may be
attributable to differences in the pathways of carcinogen-
esis among various types of human cancers. The present
study documented that rs9904341 was not associated
with the risk of HCC in Chinese han population, it’si n
line with Borbely’s study, suggesting that rs9904341
didn’t correlate with the risk of HCC. However, the nega-
tive result was perhaps due to the small sample size, so
replication of this finding in larger samples is needed.
Haplotype analysis can obtain more information than
single SNP and thus elevates the statistical power by mak-
ing an assay of several SNPs within the same gene simulta-
neously [34]. LD analysis pointed out that these loci were
in LD, therefore we made an assay of haplotypes
Table 6 Analysis of haplotypes and envioronments under different genetic models
Factor Dominant model Recessive model Additive model
b(P) OR(95%CI) b(P) OR(95%CI) b(P) OR(95%CI)
Drinking 0.00(0.999) 1.00(0.52~1.91) 0.00(0.999) 1.00(0.52~1.91) 0.00(0.999) 1.00(0.52~1.91)
HBsAg+ 3.30(< 0.001) 27.03(13.30~54.92) 3.30(< 0.001) 27.03(13.30~54.92) 3.30(< 0.001) 27.03(13.30~54.92)
H
a 4.01(< 0.001) 55.16(7.10~428.57) 4.01(< 0.001) 55.16(7.10~428.57) 4.01(< 0.001) 55.16(7.10~428.57)
C-G-C
b 0.12(0.624) 1.13(0.70~1.81) 0.24(0.486) 1.27(0.65~2.45) -0.12(0.843) 0.89(0.29~2.78)
G-C-C
b 0.56(0.031) 1.75(1.05~2.92) -0.07(0.894) 0.93(0.32~2.69) 0.18(0.762) 1.20(0.37~3.90)
G-C-T
b 0.07(0.775) 1.07(0.67~1.71) -0.77(0.023) 0.46(0.24~0.90) -0.32(0.574) 0.73(0.24~2.20)
G-G-T
b 0.27(0.256) 1.31(0.82~2.11) -0.17(0.652) 0.84(0.40~1.77) -0.08(0.885) 0.92(0.30~2.86)
AIC 1987.66 1986.23 1988.08
a The medical history of viral hepatitis type B;
b The structure of C-G-C, G-C-C, G-C-T, G-G-T haplotypes was rs8073069-rs9904341-rs1042489
Table 7 Analysis of haplotype-envioronment interactions under different genetic models
Factor Dominant model Recessive model Additive model
b(P) OR(95%CI) b(P) OR(95%CI) b(P) OR(95%CI)
HBsAg+ 3.62(< 0.001) 37.41(16.36~85.53) 3.31(< 0.001) 27.33(13.46~55.48) 3.51(< 0.001) 33.41(15.32~72.84)
H
a 3.90(< 0.001) 49.45(6.12~399.87) 3.96(< 0.001) 52.53(6.74~409.28) 3.87(< 0.001) 47.87(5.98~382.93)
G-C-T
b 0.25(0.479) 1.06(0.65~2.53) -0.93(0.149) 0.39(0.11~1.40) -0.12(0.646) 0.89(0.54~1.46)
G-C-T
b*HBsAg+ -0.59(0.122) 0.56(0.26~1.17) -0.22(0.765) 0.80 (0.19~3.38) -0.35(0.197) 0.70(0.41~1.20)
G-C-T
b*H
a 0.18(0.596) 1.19(0.62~2.30) 0.67(0.304) 0.51(0.54~7.06) 0.21(0.414) 1.23(0.75~1.64)
AIC 1986.19 1981.85 1983.92
a The medical history of viral hepatitis type B;
bThe structure of G-C-T haplotypes was rs8073069-rs9904341-rs1042489; * The interaction between haplotype and
environment.
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C-T haplotype as reference, the haplotype of G-C-T was
associated with a lower risk for HCC under the recessive
genetic model (OR = 0.46, 95%CI: 0.24~0.90). This sug-
gested G-C-T haplotype was perhaps a protective genetic
factor for HCC in Chinese han population. Nonetheless, it
requires further studies to confirm. Both HBsAg+ and the
medical history of viral hepatitis type B were risk factors
for HCC, whereas no statistically significant haplotype-
environment interaction existed.
To date, only one similar study on the correlation of sur-
vivin gene with HCC has been reported. Since polymorph-
isms often vary among different ethnic groups, additional
and lager sample size studies are required to validate the
association of survivin gene polymorphisms with HCC in
diverse ethnic populations. However, our study was con-
sidered credible, suggesting survivin gene polymorphisms
(rs8073069, rs9904341 or rs1042489) didn’t correlate with
HCC, at least in Chinese han population.
Conclusions
In conclusion, this is the first report regarding the associa-
tion of the survivin gene polymorphisms with the risk of
HCC in Chinese han population. No association between
rs8073069, rs9904341 or rs1042489 polymorphisms in sur-
vivin gene and the risk of HCC is found in the present
study, but rs8073069G-rs9904341C-rs1042489T is perhaps
a protective haplotype for HCC in Chinese han popula-
tion. Further studies will be needed to see whether survi-
vin gene polymorphism has a role in HCC in other
geographical region.
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